English

This report outlines the National Institute of Allergy and Infectious Diseases' (NIAID) updated strategic plan to combat tuberculosis. It focuses on four key priorities: enhancing fundamental knowledge of TB, advancing diagnostic research, accelerating vaccine development, and supporting strategies to treat and prevent TB.

This webpage provides an overview of hepatitis B, including its causes, symptoms, diagnosis, and treatment options. It emphasizes the importance of vaccination in preventing the spread of hepatitis B and reducing the risk of liver cancer and other serious health complications. 

This infographic provides an overview of hepatitis B, detailing its transmission, symptoms, and prevention strategies.

This video promotes the hepatitis B birth dose as a critical first step in protecting newborns from lifelong infection and liver cancer. It emphasizes that most people with hepatitis B are unknowingly infected at birth and that early vaccination is safe, effective, and the world’s first anti-cancer vaccine.

This fact sheet presents key talking points emphasizing the critical importance of administering the hepatitis B vaccine birth dose to newborns. 

This webpage presents data on newly reported chronic hepatitis C cases in Alaska from 2016 to 2023. It underscores the importance of continued hepatitis C surveillance to guide targeted testing and treatment efforts toward disease elimination.

This booklet provides comprehensive information on hepatitis C, detailing its impact on liver health, modes of transmission, symptoms, and the importance of testing and treatment. The booklet outlines the progression from acute to chronic infection, potential liver complications, and available diagnostic tests. 

This journal discusses the integration of hepatitis C management into primary care as a key strategy for eliminating the disease. It examines barriers to care, the role of direct-acting antivirals, and the importance of screening and treatment within primary care settings.

This journal examines the clinical course of autoimmune hepatitis (AIH) in Hispanic and African American patients at a South Bronx hospital. The findings contribute to a better understanding of AIH in diverse racial and ethnic groups, emphasizing the need for tailored healthcare strategies.

This journal compares the effectiveness of Heplisav-B and standard hepatitis B vaccines as boosters for healthcare workers with low immunity to hepatitis B, measured by anti-HBs antibody levels. Results show that Heplisav-B offers a significantly higher seropositivity rate (99.4%) compared to the standard vaccine (92.7%).